Literature DB >> 15577635

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.

Luisa Valer1, Luz Martín-Carbonero, Carmen de Mendoza, Angélica Corral, Vincent Soriano.   

Abstract

Over the past 5 years, 1846 HIV-infected patients underwent drug resistance testing at our institution. None out of 216 drug-naive subjects showed K65R. However, it was recognized in 53 out of 1630 antiretroviral-experienced patients (3.3%), of whom 10 had never been exposed to tenofovir. The rate of K65R increased from 0.6% in 1999 to 11.5% in 2004. The recognition of K65R correlated negatively with the presence of thymidine analogue mutations but positively with Q151M.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15577635     DOI： 10.1097/00002030-200410210-00018

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  6 in total

1.  Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.

Authors:  K Theys; J Snoeck; J Vercauteren; A B Abecasis; A-M Vandamme; R J Camacho
Journal:  J Antimicrob Chemother       Date:  2012-09-30       Impact factor: 5.790

2.  Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.

Authors:  Robert L Murphy; Nancy M Kivel; Carlos Zala; Claudia Ochoa; Phillip Tharnish; Judy Mathew; Maria Luz Pascual; Raymond F Schinazi
Journal:  Antivir Ther       Date:  2010

3.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.

Authors:  Toni M Dando; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

6.  Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

Authors:  Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.